CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes

CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes Immunology and Cell Biology 95, 803 (October 2017). doi:10.1038/icb.2017.49 Authors: Ekua W Brenu, Timothy J Bartley, Casey M Wright & Emma E Hamilton-Williams

http://feeds.nature.com/~r/icb/rss/current/~3/tI1hFYNVlPk/icb.2017.49

Source: Immunology and Cell Biology - October 10, 2017 Category: Allergy & Immunology Authors: Ekua W Brenu Timothy J Bartley Casey M Wright Emma E Hamilton-Williams Source Type: research